Parvy Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.90 M
- Company Age 29 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.90 M
- Revenue Growth 16.19%
- Profit Growth -76.82%
- Ebitda 185.01%
- Net Worth 1.22%
- Total Assets -7.55%
About Parvy Pharma
Parvy Pharma Private Limited (PPPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 June 1995 and has a history of 29 years and eight months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.90 M.
The company currently has active open charges totaling ₹8.90 M.
Vijay Godala and Bollam Reddy serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24200TG1995PTC020772
- Company No.
020772
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Jun 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Parvy Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bollam Reddy  | Director | 21-Jun-1995 | Current |
| Vijay Godala | Director | 21-Jun-1995 | Current |
Financial Performance of Parvy Pharma.
Parvy Pharma Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 16.19% increase. The company also saw a substantial fall in profitability, with a 76.82% decrease in profit. The company's net worth moved up by a moderate rise of 1.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Parvy Pharma?
In 2020, Parvy Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sri Padmavathi Breeding Farms Private LimitedVijay Godala and Bollam Reddy are mutual person
- Viyana Drugs Private Limited
Vijay Godala and Bollam Reddy are mutual person
- Vals Pharma Private Limited
Vijay Godala and Bollam Reddy are mutual person
Charges (Loans)
₹8.90 M
₹0
Charges Breakdown by Lending Institutions
- Andhra Bank : 0.70 Cr
- Others : 0.19 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Feb 2024 | Others | ₹1.90 M | Open |
| 23 Apr 2009 | Andhra Bank | ₹5.50 M | Open |
| 10 Mar 2008 | Andhra Bank | ₹1.50 M | Open |
How Many Employees Work at Parvy Pharma?
Unlock and access historical data on people associated with Parvy Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Parvy Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Parvy Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.